VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) - PowerPoint PPT Presentation

1 / 58
About This Presentation
Title:

VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE)

Description:

Structure of Penicillin binding protein 2a from MRSA strain 27r at 1.80 A resolution Adapted from a presentation by Jon Rosenberg, Infection Control and Healthcare ... – PowerPoint PPT presentation

Number of Views:1351
Avg rating:3.0/5.0
Slides: 59
Provided by: staffweb8
Category:

less

Transcript and Presenter's Notes

Title: VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE)


1
COMMUNITY ACQUIRED METHICILLIN RESISTANT
STAPHYLOCOCCUS AUREUS
Structure of Penicillin binding protein 2a from
MRSA strain 27r at 1.80 A resolution
Adapted from a presentation by Jon Rosenberg,
Infection Control and Healthcare Epidemiology,
Division of Communicable Disease Control,
California Department of Health Services
2
orBacteria Run Wild, Defying Antibiotics
A new chapter in the continuing story of
antibiotic resistance is being written in
doctors' offices across the country, as a group
of common bacteria rapidly becomes resistant to
the antibiotics that have been used to treat them
for decades.
March 2, 2004
3
3
4
U.S. Athletes Getting Superbug Skin Infections
Reuters Health Aug 21, 2003
Skin and soft tissue infections due to
antibiotic-resistant staph appear to be a growing
problem among competitive athletes in the U.S.,
according to a report released on Thursday by the
U.S. Centers for Disease Control and Prevention.
4
5
CAMRSA Summary
  • Distinct from HAMRSA
  • Clinical
  • Skin and soft tissue infections
  • Epidemiology
  • Children and young adults, summertime
  • Prisons, IVDU, sports teams, aboriginal
    populations
  • Phenotype
  • Mono-resistant/non-MDR, rapid growth
  • Genotype
  • Type IV SCCmec gene, PVL and other virulence
    factors, PFGE patterns

6
CAMRSA Summary
  • Epidemiology
  • No national surveillance
  • Emerged in 1980s, increasing, epidemic levels??
  • Pathogenicity
  • More pathogenic, transmissible than HAMRSA
  • Different from CAMSSA?
  • Risk factors
  • Limited studies suggest few identifiable risk
    factors
  • Antibiotic use usually not a risk factor

7
S. Aureus Illness and Syndromes
Prominent Cellulitis Hospital-acquired
bacteremia Hematogenous osteomyelitis Septic
arthritis Brain abscess Hospital-acquired
pneumonia Empyema Septic shock Food-borne
gastroenteritis Renal carbuncle
Sole/Most Common Furuncle or carbuncle Impetigo
bullosa Surgical wound infection Pyomyositis Botry
omycosis Acute or right-sided endocarditis Epidura
l abscess Toxic shock syndrome Scalded skin
syndrome
From Archer. Clin Infect Dis 199826117981
7
8
S. aureus Skin Infections
Furuncles (boils)
Cellulitis
Mild
Severe
9
S. aureus Why Worry?
  • Pathogenicity
  • Community infections
  • Furuncles (boils), carbuncles, endocarditis,
    toxic shock
  • Transmissibility
  • Colonized (in addition to infected) persons
    sources of transmission
  • Resistance
  • Decreasing treatment options

10
Pathogenesis of S. aureus Infections
  1. Colonization
  2. Local infection
  3. Systemic dissemination and/or sepsis
  4. Metastatic infection
  5. Toxinosis

11
Staphylococcus aureus Colonization
  • Humans natural reservoir
  • Anterior nares
  • 30-50 healthy adults colonized at any one time
  • 60 colonized intermittently
  • 20 persistently colonized
  • 20 never colonized
  • Axillae, vagina, pharynx, damaged skin, rectum
  • Hands, intact skin colonized transiently
  • Clearance of nasal colonization eliminates hand,
    skin carriage

12
Rates of S. aureus nasal carriage in various
populations
From Kluytmans et al. Clin Microbiol Rev, July
1997
12
13
Transmission/Pathogenesis Nosocomial S. aureus


Patients
Negative
Colonized
Infected
Invasive devices
Immune suppression
14
Transmission/Pathogenesis Nosocomial MRSA


Patients
Negative
Colonized
Infected
Invasive devices
Antibiotic
Immune suppression
15
Transmission/Pathogenesis Community S.
aureus/MRSA
Direct inoculation?
Persons
Negative
Colonized
Infected
Break in skin
16
Emergence of Resistance in S. aureus
Drug Year drug introduced Years to report resistance Years until 25 rate in hospitals Years until 25 rate in community
Penicillin 1941
1-2
6
5-20
Methicillin 1961

40-50

(projected 2001-2010)
25-30
lt1
Vancomycin 1956
? ?
40
Chambers, EID 7178-182, 2001
17
Methicillin-resistant Staphylococcus aureus
(MRSA) in the community who's watching?
  • Commentary in Lancet. 1995 Jul 15346(8968)132-3.
  • Asked to comment on Layton MC, Hierholzer WJ,
    Patterson JE. The evolving epidemiology of
    methicillin-resistant Staphylococcus aureus at a
    university hospital. Infect Control Hosp
    Epidemiol 19951612-17
  • Among 87 patients with MRSA 36 (41) were
    community-acquired, and of these 8 (22) had no
    discernible risk factors

18
Is MRSA Present and Increasing in the Community?
  • Little data
  • Most community infection not cultured
  • Staphylococcal infections are not reportable
  • Methicillin resistance is not reportable with few
    exceptions
  • Community acquisition cannot be distinguished
    from nosocomial without patient interviews

19
CAMRSA in Hospital Pediatrics
  • Number children hospitalized at U Chicago with
    CAMRSA from 8 in 1988-1990 to 35 in 1993-1995
  • Prevalence of CAMRSA without identified risk
    factors
  • 10 per 100000 admissions in 1988-1990
  • 259 per 100000 admissions in 1993-1995
  • Herold et al,. JAMA 1998 Feb 25279(8)593-8
  • Updated 1998-1999
  • 23 hospitalized children with MRSA
  • 10 community-acquired, 208/100,000
  • Hussain et al, Pediatr Infect Dis J December 2000

20
CAMRSA in Hospital Pediatrics
  • Driscoll Childrens HospitalCorpus Christi, TX
  • 1990-2000 196 MRSA isolations
  • 7 in 1990-1996, 53 in 1997-2000, 35 in 2000
  • 128 medical record reviews
  • 60 (47) community acquired
  • 53 (88) no identifiable risk factors
  • Fergie and Purcell, Pediatr Infect Dis J. 2001
    Sep 20860-3

21
CAMRSA in Dermatology Outpatients
  • Prevalence of MRSA in dermatology outpatient
    clinics, Baylor College of Medicine
  • 1986-1987 lt0.9
  • 1988-1996 gradual increase from 1.5 to 11.9
  • Increasing resistance to ciprofloxacin and
    tetracycline
  • Price et al,. South Med J April 1998

22
CAMRSA in Rural American Indian Community
  • Indian Health Service in New Mexico
  • Medical records 1997
  • 112 S. aureus isolates
  • 62 (55) MRSA
  • 46 (74) community acquired
  • No difference risk factors vs. CAMSSA
  • PFGE distinguished community acquired from
    nosocomial
  • Groom et al. JAMA 2001 Sep 12286(10)1201-5

23
CAMRSA Colonization in Community Pediatrics
  • 500 children lt 16yo U. Chicago outpatient clinic
    to receive well child care
  • 24.4 colonized with S. aureus
  • Three (2.5) MRSA colonized
  • Hussain et al. Pediatr Infect Dis J August 2001
  • 500 children Nashville well child care visits
  • Four (8) MRSA colonized
  • Nakamura et al. Pediatr Infect Dis J October 2001

24
CAMRSA Colonization in Community
  • Bellevue Hospital Pediatric Clinic
  • 275 children and 225 guardians
  • S. aureus colonization 35 children, 28
    guardians
  • One child with nosocomial MRSA
  • Shopsin et al. J Infect Dis J 2000182359-62

25
MRSA Colonization in Community
  • Community-acquired methicillin-resistant
    Staphylococcus aureus a meta-analysis of
    prevalence and risk factors
  • Pooled CA-MRSA prevalence among 5932 patients
    from 27 retrospective studies was 30.2
  • Pooled MRSA colonization rate among community
    members was 1.3
  • Among studies that excluded persons with health
    care contacts, the MRSA prevalence was 0.2
  • Salgado, Farr, Calfee. Clin Infect Dis
    January 2003

26
CAMRSA Risk Factors
  • Prospective observation children 2/2000-11/2000,
    Baylor
  • 63 CAMRSA vs 81 CAMSSA
  • No difference in risk factors (antibiotic
    exposure, day-care, underlying illness, previous
    hospitalizations, health care worker in home or
    contact, health care visits)
  • Sattler et al. Pediatr Infect Dis J October 2002

27
CAMRSA Nosocomial Transmission
  • Hospital Transmission of CAMRSA among Postpartum
    Women
  • Departments of Pediatrics, Columbia University,
    New York
  • 8 women skin and soft-tissue MRSA infections mean
    time of 23 days (range, 4-73 days) after delivery
  • 4 cases of mastitis (3 progressed to breast
    abscess), a postoperative wound infection,
    cellulitis, pustulosis
  • Identical by PFGE to CA-MRSA strain MW2
  • Route of transmission not discovered cultures
    from employees of the hospital, the hospital
    environment, and newborns negative
  • Saiman et al. Clin Infect Dis. 2003 Nov
    1537(10)1313-9

28
CAMRSA Familial Transmission
  • Familial carriage of methicillin-resistant
    Staphylococcus aureus and subsequent infection in
    a premature neonate
  • Index patient MRSA infection
  • Infant sibling admitted 7 months previously MRSA
    infection
  • Nasal Cultures from parents and two other
    siblings yielded identical MRSA from mother and
    sibling
  • Hollis et al. Clin Infect Dis. 1995
    Aug21(2)328-32

29
Surveillance Definition of CAMRSA
  • Positive culture for MRSA obtained within 48
    hours of admission (if hospitalized)
  • No history of hospitalization in past year
  • No history of surgery in past year
  • No history of long-term care in past year
  • No history of dialysis in past year
  • No permanent indwelling catheters or percutaneous
    medical devices
  • No prior history of MRSA infection or colonization

30
CAMRSA Surveillance Minnesota 1996-98
  • Cases from 10 hospitals
  • 354 patients (median age, 16 years)
  • 299 (84) skin infections
  • 103 (29) hospitalized
  • More than 90 of isolates susceptible to all
    agents tested, with exception of ?-lactams and
    erythromycin
  • 334 treated, 282 (84) initially treated with
    agents to which their isolates were
    nonsusceptible
  • 174 tested, 150 (86) 1 PFGE clonal group
  • Naimi et al. Clin Infect Dis October 2001

31
CAMRSA Surveillance Minnesota 2000
  • 4,612 patients with S. aureus identified at 10
    sentinel sites (total number S. aureus
    unavailable at two sites)
  • 1164 (25) were MRSA (range 10-50)
  • 994 (85) were HA-MRSA
  • 133 (11) were CO-MRSA (range 4-50) after
    patient interview
  • 37 (3) not enough information to classify
  • 13 of presumptive CO-MRSA cases were
    reclassified as HA-MRSA after interview
  • Courtesy Kathy Ledell, Minnesota Department of
    Health

32
Age Distribution, Hospital Acquired MRSA,
Minnesota, 2000
Courtesy Kathy Ledell, Minnesota Department of
Health
32
33
Age Distribution, Community Onset MRSA,
Minnesota, 2000
Courtesy Kathy Ledell, Minnesota Department of
Health
33
34
Month of Culture, Hospital Acquired MRSA,
Minnesota, 2000
Courtesy Kathy Ledell, Minnesota Department of
Health
34
35
Month of Culture, Community Onset MRSA,
Minnesota, 2000
Courtesy Kathy Ledell, Minnesota Department of
Health
35
36
Susceptibility of MRSA Isolates by
Antimicrobial Agent, Minnesota 2000
Antimicrobial
Courtesy Kathy Ledell, Minnesota Department of
Health
36
37
Susceptibility Trends, Community Onset MRSA,
1996-2001
  • Susceptibility trends from 1996-2001 were
    analyzed
  • Susceptibilities decreased over time
  • Erythromycin 71 to 46, x2 trend16.5, plt0.001
  • Ciprofloxacin 92 to 80, x2 trend15.2, plt0.001
  • Clindamycin 90 to 84, x2 trend 2.7, p0.099
  • No significant change in susceptibilities to
    gentamicin, rifampin, tetracycline,
    trimethoprim-sulfamethoxazole, or vancomycin
  • Preliminary data 2002 erythromycin 42,
    ciprofloxacin 77, clindamycin 84

Courtesy Kathy Ledell, Minnesota Department of
Health
38
Treatment of CAMRSA Are Antibiotics Needed for
Abscesses?
  • 69 children CA-MRSA skin and soft tissue abscess
  • Treatment drainage in 96 and wound packing in
    65
  • All treated with antibiotics, only 5 (7)
    appropriate before culture
  • Significant predictor of hospitalization was
    having a lesion initially gt5 cm
  • 58 patients initially given ineffective
    antibiotic, antibiotic active against CA-MRSA
    given to 21 after cultures
  • No significant differences in response in those
    who never received an effective antibiotic than
    in those who did
  • Incision and drainage without antibiotic therapy
    effective management of CA-MRSA skin and soft
    tissue abscesses lt5 cm in immunocompetent children

Lee et al, Pediatr Infect Dis J February 2004
39
Treatment of CAMRSA
  • Trimethoprim-sulfamethoxazole
  • Bacteriostatic, variable resistance, limited
    clinical experience vs. serious infections
  • Clindamycin need to test for inducible
    resistance
  • Rifampin
  • Active, cannot use alone (development of
    resistance)
  • Vancomycin (parenteral)
  • Linezolid (expensive, bacteriostatic)

40
CAMRSA - Severity
  • Four Pediatric Deaths from Community-Acquired
    Methicillin-Resistant Staphylococcus aureus --
    Minnesota and North Dakota, 1997-1999
  • MMWR August 20, 1999 / 48(32)707-710
  • All patients in this report were initially
    treated with a cephalosporin antibiotic
  • MRSA isolates from these four cases were
    susceptible to all antimicrobial agents tested
    except beta-lactams

41
Staphylococcal PVL Potent Dermonecrotic Toxin
  • The Panton-Valentine leukocidin of Staphylococcus
    aureus was shown to exhibit a potent
    dermonecrotic effect when injected intradermally
    into rabbits
  • PVL belongs to group of exotoxins that damage the
    membrane of host defense cells
  • Ward and Turner. Infect Immun May 1980

42
PVL in Primary Skin Infections and Pneumonia
  • 172 S. aureus strains screened for PVL genes
  • 93 of furunculosis and 85 of severe necrotic
    hemorrhagic pneumonia
  • 55 of cellulitis, 50 of cutaneous abscess, 23
    of osteomyelitis, 13 of finger-pulp infection
  • Not detected
  • infective endocarditis, mediastinitis,
    hospital-acquired pneumonia, urinary tract
    infection, enterocolitis, toxic-shock syndrome
  • Lina et al. Clin Infect Dis November
    1999

43
CAMRSA and PVL
  • 14 CAMRSA cases in previously healthy patients
  • 11 skin or soft-tissue infections
  • 2 died of necrotizing pneumonia
  • Panton-Valentine leukocidin genes in all
  • Dufour et al. Clin Infect Dis 2002 35000000

44
CAMRSA Carrying PVL Genes Worldwide Emergence
  • 117 CA-MRSA isolates
  • 33 United States
  • 67 Europe (61 France and 6 Switzerland)
  • 17 Oceania (Australia, New Zealand, Western
    Samoa)
  • Most isolates primary skin and soft tissue
    infections
  • All strains carried Panton-Valentine leukocidin
    locus
  • Distribution of other toxin genes specific to
    each continent

Vandenesch et al. Emerging Infectious Diseases
Vol. 9, No. 8 August 2003
45
Growth Rate of CAMRSA
  • CAMRSA strains grow faster than HAMRSA strains
  • Mean doubling time 28 minutes vs. 38 minutes
  • Enhance competitive survival in absence of
    antibiotics
  • Did not compare to CAMSSA
  • Okuma et al. J Clin Microbiol November 2002

46
Whole genome sequencing of MRSA
  • Whole genome sequences of N315 (MRSA strain
    1982), Mu50 (VISA strain 1997)
  • Complex mixture of genes
  • Many acquired by lateral gene transfer
  • Antibiotic resistance genes carried either by
    plasmids or by mobile genetic elements
  • Kuroda M et al. Lancet April 2001

47
S aureus chromosome
From Kuroda et al. Lancet 2001 Apr 21
47
48
Antibiotic Resistance Genes in MRSA
Kuroda et al. Lancet April 2001
48
49
Staphylococcus Cassette Chromosome
  • Methicillin resistance gene of MRSA carried by
    novel genetic element, SCCmec
  • Integration into and excision mediated by unique
    set of recombinase genes, ccrA and ccrB

Katayama, Ito, Hiramatsu. Antimicrobial Agents
Chemotherapy June 2000
50
Structures of SCCmec
Ito et al. Drug Resistance Updates 2003
50
51
CAMRSA Carrying PVL Genes Worldwide Emergence
  • All 117 CA-MRSA strains shared a type IV SCCmec
    cassette
  • PFGE and MLST analysis indicated distinct genetic
    backgrounds associated with each geographic
    origin
  • Within each continent, genetic background of
    CA-MRSA strains did not correspond to
    hospital-acquired MRSA

Vandenesch et al. Emerging Infectious Diseases
Vol. 9, No. 8 August 2003
52
CAMRSA - Outbreaks
  • Community outbreaks have occurred among
  • Injection-drug users
  • Aboriginals in Canada, New Zealand, and Australia
  • Native Americans/Alaska Natives in United States
  • Players of close-contact sports (scrum pox)
  • MSM?
  • Institutional outbreaks
  • Prisons, jails, developmentally disabled
  • More than S. aureus in past?

53
Methicillin-Resistant Staphylococcus aureus
Infections Among Competitive Sports Participants
--- Colorado, Indiana, Pennsylvania, and Los
Angeles County, 20002003 MMWR August 22, 2003 /
52(33)793-795
  • Colorado 4 fencers, 1 household contact
  • Pennsylvania 10 college football, 7 hospitalized
  • Los Angeles 2 college football players
    hospitalized

53
54
CAMRSA in Los Angeles
  • Resistance
  • Resistant to ciprofloxacin, erythromycin
  • Sensitive to trimethprim/sulfa, rifampin,
    clindamycin, vancomycin
  • Also linezolid, Synercid
  • Los Angeles Jail
  • 165,000 prisoner/year, 1,000 infections in past
    year
  • Poor hygienic conditions
  • Football team
  • Gay men
  • Extent of problem undefined
  • Mode of transmission to be determined

55
Pediatric CAMRSA in Los Angeles
  • MRSA reportable May 5 - November 7, 2003
  • Hospitalized children (lt18 years) excluding
    nosocomial
  • First 13 weeks surveillance
  • 62 cases, diverse races, ethnicities, mean age
    6.9 years
  • Cellulitis 50 of cases
  • Average length of hospitalization 7 days (range
    of 1-33 days)
  • 25 initially thought to be spider, insect bites
  • 24 exposed to another individual in home with
    lesions month before the childs infection
  • 12 of contacts in the home subsequently
    developed skin lesion
  • 11/13 initially treated with beta-lactam
    antibiotics

56
Prevention and Control of CAMRSA
  • Hygiene
  • Hand hygiene
  • Showering with soap
  • Cleaning and disinfection
  • Laundering personal items such as towels after
    each use
  • Cleaning or laundering shared materials
  • Wound care
  • Covering cuts and abrasions until healed
  • Consulting a health-care provider for wounds that
    do not heal or appear infected, diagnosis and
    treatment
  • Role for decolonization if recurrence?

57
Questions
  1. At what prevalence of resistance should empiric
    treatment change?
  2. What is role of antibiotics vs. ID?
  3. What is optimal antibiotic therapy?
  4. What is best prevention strategy
  5. What is role for decolonization?
  6. Can we answer these questions without
    surveillance of local population

58
What can we learn from surveillance?
  • Identify potential risk factors
  • Explore potential prevention strategies
  • Explore clinical management issues
  • Follow trends regarding numbers of cases,
    susceptibilities, and at risk populations
  • Explore potential virulence and host factors
Write a Comment
User Comments (0)
About PowerShow.com